Olmesartan/Hct Krka (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmesartan/Hct Krka, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It is combined with hydrochlorothiazide to treat hypertension in adult patients. GNH USA supplies Olmesartan/Hct Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan/Hct acts on the renin‑angiotensin‑aldosterone system to lower elevated blood pressure. - Hypertension: provides sustained reduction of systolic and diastolic blood pressure in essential hypertension. - Hypertension with fluid retention: enhances diuretic effect to control volume overload. - High‑risk cardiovascular patients: contributes to risk reduction when combined with lifestyle measures.

Common Side Effects: - Dizziness: mild to moderate light‑headedness, especially after the first dose. - Headache: transient cephalic discomfort. - Fatigue: general tiredness without specific cause. - Increased urination: due to the diuretic component. - Electrolyte imbalance: mild changes in potassium or sodium levels.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Acute renal impairment: sudden decrease in kidney function. - Hyperkalemia: elevated potassium that may affect cardiac rhythm. - Angioedema: swelling of face, lips, tongue, or airway. - Life‑threatening electrolyte disturbances: severe hyponatremia or hypokalemia.

Olmesartan/Hct should be used with careful clinical monitoring. - Blood pressure monitoring: check regularly to avoid excessive lowering. - Renal function assessment: evaluate serum creatinine before and during therapy. - Electrolyte surveillance: monitor sodium and potassium levels, especially with diuretic use. - Pregnancy avoidance: contraindicated in the second and third trimesters due to fetal risk. - Elderly dose consideration: start with lower dose and titrate cautiously. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan/Hct may interact with several medicines that affect blood pressure, renal function, or electrolyte balance. Major Interactions (Avoid): - Aliskiren (in diabetic patients): risk of renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics: may cause dangerous hyperkalemia. - Lithium: increased lithium levels and toxicity. - ACE inhibitors: additive effect on potassium and renal function. - NSAIDs: may blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives: may require dose adjustment to prevent hypotension. - Non‑potassium‑sparing diuretics: monitor electrolytes. - Antidiabetic agents: blood glucose may improve, requiring dose changes. - CYP450 inhibitors (e.g., azole antifungals): may increase olmesartan levels. - Antacids containing aluminum or magnesium: may reduce absorption of olmesartan.